The BioWorld Biopharmaceutical Index (BBI) closed November with a modest 3.58% gain for the year, a sharp decline from its 16 ...

Ionis Pharmaceuticals Inc. CEO Brett Monia predicted that diagnoses of familial chylomicronemia syndrome (FCS) will ...

Bioarctic AB has entered into a global exclusive license agreement with Bristol Myers Squibb Co. for Bioarctic’s ...

A spate of year-end collaborations highlights growing enthusiasm for expanding use of automated insulin delivery devices or ...

Arbor Biotechnologies Inc. has gained IND clearance from the FDA for ABO-101, a novel gene editing therapeutic designed to ...

Merit Medical Systems Inc. received an early holiday gift this year, reporting that its Wrapsody cell-impermeable ...

Onconic Therapeutics Inc., a subsidiary of Jeil Pharmaceutical Co. Ltd., saw its shares (KOSDAQ:476060) ascend for two consecutive days after debuting with a ₩20.15 billion (US$13.89 million) IPO on ...

The end of the year will be the end of an era at the FDA, as Bob Temple shuts his door at CDER for the last time Dec. 31.

Bio-path Holdings Inc. has conducted preclinical studies of BP-1001-A, a drug product modification of prexigebersen, confirming its effectiveness in affecting insulin signaling for the potential ...

The first acellular tissue engineered vessel for adults with vascular trauma in a bodily extremity has been approved by the U.S. FDA. Symvess, which comes from regenerative tissue developer Humacyte ...

Shares in Zealand Pharma A/S (CO:ZEAL) dropped 22.4% to as low as DKK587 (US$82.16) on Dec. 20, after the U.S. FDA issued a complete response letter (CRL) for glepaglutide in the treatment of short ...

The regular use of agonists of the μ-opioid receptor for acute pain relief usually leads to tolerance, respiratory depression, constipation and importantly, abuse potential.